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Nontypeable Haemophilus influenzae (NTHi) or nonencapsulated Haemophilus 
influenzae has been connected to such diseases as pneumonia, bacteremia, meningitis and 
sepsis in adults. NTHi is also linked to 25-35% of the roughly 25 million annual cases 
(within The United States) of acute otitis media (ear infections) in children. Vaccines 
against encapsulated strains of Haemophilus influenzae have been proven effective; yet, 
no vaccines have been produced to protect against NTHi infection. The 16-kDa outer 
membrane lipoprotein P6 has been shown to be nearly homologous between NTHi 
strains, making it one of the leading vaccine candidates for NTHi. However, it was 
recently demonstrated, using flow cytometry, confocal microscopy, and other 
biochemical methods, that P6 exhibits dual orientation in the outer membrane of NTHi. 
Specifically, a small percentage of cells contain P6 which faces out of the cell while a 
much larger percentage of cells contain P6 which faces in toward the periplasm. 
Nonetheless, these studies were only performed on a single strain of NTHi, which was 
cultured in a laboratory under aerobic conditions. In order to gain insight into P6’s in vivo 
orientation(s), similar studies were performed on multiple clinically relevant strains of 
NTHi, cultured under microaerophilic and anaerobic conditions as well as physiological 
pH conditions which more closely resemble the environment of the middle ear. We 
conclude that all tested strains of NTHi (cultured under various pH and oxygen 
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Acute Otitis Media 
 Otitis media (OM) occurs commonly in children and less commonly in adults as 
inflammation of the inner ear, predominantly caused by bacteria. Otitis media, i.e., ear 
infection, can be further classified into three major classes: acute otitis media (AOM), 
otitis media with effusion (OME), and chronic otitis media (COM). AOM results from an 
acute or abrupt onset of a bacterial infection of the middle ear with a short duration (<6 
weeks). OME occurs when there is fluid present in the middle ear, and COM is classified 
by a long term infection within the middle ear (>6 weeks) [1]. In United States, OM is the 
second most common reason for pediatric visits behind the common cold, and the most 
frequent reason for antibiotic pediatric prescriptions [2, 3]. Furthermore, in the US, OM-
related costs (medical costs plus lost wages) total over $5 billion per year [4]. The 
extreme cost to health care alone underlines the urgent need for improvements in 
treatment for and prevention of OM. 
OM is not sequestered to the more impoverished countries, which may lack 
modern medical technologies. This disease remains unbiased and is widespread in both 
the developed and undeveloped countries [5]. In Latin America and the Caribbean, the 
disease burden (impact of a health problem measured by financial cost, mortality and 
morbidity) of AOM is between 8,200,00 and 12,900,000 in children (< 5 years) [3]. 
Additionally, OM complications result in annual reported deaths ranging from 28,000 to 
50,000, which are largely attributed to children contracting meningitis and brain 
abscesses from the initial infections or other exacerbated forms of the bacterial infection 
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[2, 5]. While OM can clear naturally and without medical intervention in some children, 
aggressively virulent infections can have more dire outcomes such as permanent hearing 
impairment.   
Otitis media occurs due to the invasion of bacteria, viruses, or combination of 
both into the middle ear. The most common pathogens which cause OM are nontypeable 
Haemophilus influenzae (NTHi), Streptococcus pneumoniae (S. pneumo), and Moraxella 
catarrhallis (M. cat). These bacteria often live harmlessly as commensal organisms for 
extended periods of time in the nasopharynx. However, when colonization density of the 
organism(s) is increased upper respiratory infection occurs, resulting in a gain of entry of 
the organism(s) into the middle ear. This is followed by an immune response and 
subsequent inflammation within the middle ear. Bacterial OM is commonly associated 
with an upper respiratory tract infection (URTI) [6, 7]. Studies have revealed that by the 
age of three, 80% of children will have suffered from at least one episode of OM, and out 
of those children who have suffered at least one OM episode, 40% of them will develop 
reoccurring otitis media and suffer from six or more episodes by the time they are seven 
years old [2-5, 8]. OM is a ubiquitous and sometimes deadly infection, plaguing children 
across the world without prejudice.  
 
Signs and Symptoms of OM 
 Otitis media pathogenesis is believed to be multifactorial and presents generally 
with a combination of ear pain, fever, erythema (reddening of the skin due to the 
infection which causes dilation of the blood capillaries), bulging of the tympanic 
membrane, viral/bacterial invasion, and otorrhea (ear discharge), [4-6, 9, 10]. Gastro-
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esophageal reflux, smoke exposure, and autoimmune complications can exacerbate OM 
and/or increase vulnerability to OM [5, 10]. If left untreated, OM can progress into more 
serious illnesses or ailments, as discussed above, such as meningitis or hearing loss [2].  
 
Viruses and OM 
OM resulting from co-infection with bacteria and upper respiratory viruses 
characteristically dominates the pathogenesis of the disease. Furthermore, co-infection of 
bacteria and viruses results in anywhere from 28-78% of nasopharynx and middle ear 
infections [6, 10-12]. Episodes of OM are frequently preceded by a viral infection, but 
the biological/pathological reason behind this phenomenon is not known. Scientists 
suggest, though, that the viral infection has an effect on OM development through the 
existing mucosal epithelial damage, decrease in mucociliary functioning, and cytokine 
responses [6, 13]. It was also shown that during the course of a viral infection, the 
carriage rate of OM-causing bacteria increased in the nasopharynx, which predisposed a 
child to a future OM infection [13]. The most common viruses associated with OM are 
respiratory syncytial virus (RSV), coronavirus, influenza, and adenovirus. Researchers in 
the United States have found that 97% of children between the age of 0.5-3 years have 
had at minimum one upper respiratory tract infection (URTI) caused by a virus annually 
[6]. Additionally, the study showed that 61% of those children suffering from URTI also 
had OM [6]. Interestingly, certain forms of OM were more common with certain viruses. 
AOM was typically involved in co-infection with coronavirus, adenovirus, or RSV while 
OME typically co-infected with influenza virus or enterovirus [10, 14].  
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Long-term effects of OM 
 Recurrent OM has been linked to hearing impairment, speech impairment, 
attention deficit, reading problems, language learning problems, and cognitive/behavioral 
disorders. OM is the foremost cause of hearing loss (mucin inhibits the transmission of 
sound waves from the middle to inner ear) [5]. The rapid development of the eustachian 
tube (ET) in babies favors tubal blockage, which can be intensified by pollutants, 
allergens, toxins, and viral infections [6]. The main function of the Eustachian tube is 
ventilation, protection, and clearance of the middle ear (see Figure 1.0). Under normal 
conditions, the process of swallowing will equalize the pressure in the ET.  However, 
impediment by bacteria causes negative pressure to build up within the middle ear, 
resulting in effusion. [10]. If this impediment persists for a long period of time, the child 
can acquire early conductive hearing loss (difficulty or loss of ability to conduct sound 
waves though the outer ear, tympanic membrane, and middle ear). Further, children with 
conductive hearing loss have been shown to have a greater predisposition to 
abnormalities in brainstem physiology, language skills, and binaural hearing [15]. Since 
OM results in diminished hearing capacity associated with a blocked Eustachian tube, 
children who experience recurrent ear infections have challenges distinguishing between 
vowel and consonant sounds. Over time, these impairments can lead to language learning 
problems and/or delayed speech. Approximately 10% of children with COM also exhibit 
learning disabilities and/or impaired language development problems [16]. Prevention of 
OM could therefore decrease the impact of the secondary complications resulting from 
hearing loss by ear infections and improve the quality of life of many children.  
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Figure 1.0: Diagram of the outer, middle, and inner ear. (Image from Harvard-WM.Org) 
 
Diagnostic and Treatment Methods 
Children’s Eustachian tubes are shorter and narrower than those of adults. In 
addition, the angle between the nasopharynx and the Eustachian tube is more horizontal 
in children. As a result, bacteria are more easily trapped in the inner ear, allowing for OM 
[4]. OM specialists also suggest that babies and children have less mature immune 
systems, resulting in enhanced susceptibility to OM infection [17, 18]. Further 
complicating matters, the small size and collapsible nature of the external auditory canal 
makes otomicroscopic examination of the auditory canal and tympanic membrane 
problematic. Challenges in orthoscopic inspection of the ear canal and tympanic 
membrane result in countless misdiagnoses of OM; as a result, the number of genuine 
incidences of OM is unknown. In turn, antibiotics are often prescribed without true 
confirmation of OM, thus exacerbating the growth of antibacterial resistant bacteria [9]. 
A multinational study with the United States, Australia, Belgium, Great Britain, Israel, 
New Zealand, Canada, Switzerland, and The Netherlands revealed that general 
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practitioners were only 58% certain of AOM diagnosis with infants, 66% certain with 
toddlers, and 73% certain with older children [19]. 
 One approach taken by some pediatricians to correct the overuse of antibiotics 
was to delay OM treatment for 48 to 72 hours after diagnosis, the strategy being that the 
child’s immune system would clear the infection by itself. However, the effect of this 
treatment method has not been studied significantly [20]. Furthermore the “wait and see” 
approach sometimes increases the amount of inflammation of the middle ear and can 
exacerbate Eustachian tube dysfunction. For these reasons, the “wait and see” approach is 
not suggested for children less than 2 years of age whose adaptive immunity may not be 
capable of combating a larger infection [10]. One potential negative effect of the “wait 
and see” method is the development of mastoiditis (inflammation of the mucosal lining of 
the mastoid), which is highly painful to the child [21]. 
OM is also behind the most commonly performed childhood operation, 
tympanostomy tube insertion [5, 22]. Usually children with a pure tone threshold over 30 
dB who have chronic OME for over three months and show unwanted structural changes 
to the tympanic membrane will undergo a tympanostomy tube insertion [23]. 
Approximately 667,000 children (2006 report) younger then 15 years of age received 
tympanostomy tubes. By age three, 1 in 15 children will have tympanostomy tubes, with 
numbers doubling in the case of children enrolled in daycare [22, 24]. Although the 
operation is considered routine, all operations have risks involved. Anesthesia-related 
deaths for children undergoing surgical procedures, like tympanostomy tube insertion, 
ranges from 1 in 10,000 to 1 in 45,000 procedures. These statistics are due, in part, to 
children being more disposed to laryngo/bronchospasms. Other complications, like 
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postoperative otorrhea, develop in approximately 5-10% of patients [10, 25]. Post-
tympanostomy tube otorrhea (PTTO) is caused by the same bacterium that initially 
causes OM. Further, antibiotics prescribed for pre and/or postoperative treatment can also 
lead to the increase in antibiotic resistance bacteria [23].   
 
Bacterial Resistance and the Need for Vaccines  
The widespread use of antibiotics to treat OM has significantly increased health 
care costs and created notable disadvantageous side effects. The chief negative effect is 
that overuse of antibiotics creates environmental pressure for the selection of antibiotic 
resistant bacteria [20, 23]. AOM is the leading disease for which pediatricians prescribe 
antibiotics [3, 16, 26]. In one study, as much as one-third of AOM diagnosed patients 
were found to have normal ears; these misdiagnosed patients were often prescribed 
antibiotics, thus adding to environmental pressure favoring antibiotic-resistant bacteria 
[6]. Amoxicillin is commonly prescribed due to its superlative penetration of the middle 
ear [10]. Overuse of the drug has resulted in resistance to amoxicillin doubling in five 
years (since 2004). β-lactamase-containing antibiotics, cephalosporins, macrolides, and 
roquinolones have all seen a similar upward trend in bacterial resistance [27]. 
Additionally, several of the bacterial strains that are resistant to the antibiotic penicillin 
are also resistant to antibiotics akin to tetracycline, chloramphenicol, and erythromycin 
[28]. Not unexpectedly, an increase in antibiotic resistance has also been seen in all three 
of the major bacteria that contribute to otitis media: NTHi, M. cat, and S. pneumo [4, 29]. 
The purpose of an antibiotic administered to children with AOM is to clear the 
infection in the middle ear, especially within the bacterial effusion. However, the effect 
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of antibiotics is far-reaching, often disturbing/killing much of the normal flora in the 
oropharynx, mouth, gastrointestinal, and/or genital tract. This phenomenon can lead to 
replacement of the eliminated bacterial cells with antibiotic-resistant bacteria or the 
colonization of new resistant organisms [13].  
 Another adverse effect of long-term antibiotic prophylaxis is the suppression of 
the symptoms of a disease without eradicating the disease itself. The outcome of such 
suppression will ultimately result in reoccurring COM or unfavorable antibiotic 
experiences [30]. One unfavorable event may be bacterial biofilm formation. Biofilms are 
created by the bacteria to shield their community from external forces. Biofilms protect 
the bacteria from most host immune defenses, antimicrobial agents, and surfactants [31, 
32]. These biofilms may be one of the reasons why 20% of AOM cases are unresponsive 
to antibiotic treatment all together [6, 33]. Because of the many problems associated with 
treatment of the disease, one potentially more effective course of action in the fight 
against OM is prevention, specifically in the form of a vaccine.  
 Wide scale immunization of children with a pneumococcal conjugate vaccine has 
helped to significantly decrease the cases of AOM caused by S. pneumo. The vaccine 
Prevnar™/Prevenar-13™ created by Pfizer/Wyeth (USA) was released for public 
immunization in the United States in 2010 to protect against one of the three pathogens 
that cause OM: Streptococcus pneumoniae. This heptavalent conjugate vaccine was 
demonstrated to have 57% efficiency protecting individuals against infections by the 
serotypes of S. pneumo which are contained within the vaccine [3, 32, 34]. Unfortunately, 
concurrent with the increase in immunization against S. pneumo, there has been an 
increase in AOM infections by NTHi and M. cat [3, 35, 36]. Evidently, NTHi and M. cat 
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are filling the niche that S. pneumo left behind. In addition, strains of S. pneumo not 
contained within the vaccine are also expected to increase in virulence and their ability to 
cause infection. Currently, there are no vaccines to protect against infection by NTHi or 
M. cat [37]. 
 
Chronic Obstructive Pulmonary Disease (COPD) and NTHi 
The incidence of chronic obstructive pulmonary disease (COPD) is increasing; it 
is now the fourth leading cause of death globally [38-40]. This disease presents with 
progressively worse restricted airflow, which is usually irreversible. The restricted 
airflow of COPD is believed to result from peribronchiolar fibrosis (uncontrolled or 
prolonged repair function that ultimately results in matrix deposition), goblet cell 
metaplasia, or extreme mucus production [39, 41, 42]. Exacerbations from COPD 
damage the elasticity of the lungs, hamper the gas-exchange surface area, and increase 
airway obstruction leading to lung disease [39]. 
 Exposer to cigarette smoke (CS) has been correlated to incidents of COPD. 
However, only ~30% of smokers develop COPD [43, 44]. This statistic suggests that 
other factors contribute to the onset of COPD, for example genetic factors, infections, and 
atypical host responses [39]. In COPD patients who smoke, inflammation and decreased 
lung function can continue to worsen, even after the patient quits smoking [45]. 
Respiratory pathogens, viruses, and fungi are commonly found in patients 
suffering from COPD; scientists suggest that toxins and viral RNA can contribute to the 
uptick and progression of the disease [46-48]. Bacterial infection is also linked to 
accelerated decrease in lung function [42]. One such upper respiratory pathogen is NTHi. 
  10 
 
It has been shown (in mice) that chronic exposure to NTHi bacterial lysates induces 
airway inflammation [49], and that in addition to CS, exposure to bacteria is responsible 
for the induction of COPD’s characteristic features such as emphysema, lung 
inflammation, and airway remodeling [39].  
NTHi is frequently isolated from COPD patients during exacerbations [39, 50], 
and the recent development of new strains of NTHi has resulted in increased lower 
respiratory tract infections [49, 51-53]. Furthermore, when human bronchial epithelial 
cells were cultured with endotoxin from NTHi, a notable increase in cytokines were 
observed, including the inflammatory molecules IL-6, IL-8, and TNF-α [49, 50]. These 
results point to NTHi as a major cause of airway inflammation in COPD. In summary, 
the development of a vaccine against NTHi could potentially provide protection against 
otitis media in children and COPD in adults.  
 
P6 from NTHi: A leading vaccine candidate 
In children, antibodies (IgG, IgM, and IgA) to NTHi may not reach adult levels 
until they are around 4 years of age, leaving young children particularly vulnerable to 
NTHi colonization and infection [37, 54]. In an effort to decrease the occurrence of OM 
(as well as COPD) and the need for antibiotics, especially in children, our research 
group’s strategy focuses on prevention via vaccination.  
There are a variety of vaccine types that can be employed for protection against 
both bacterial and/or viral infections. Live attenuated vaccines contain the whole live 
pathogen that has been weakened (typically by chemicals) and thus can no longer cause 
disease. While this type of vaccine yields a strong antibody response and may provide 
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lifelong immunity to the pathogen with fewer dosages, there is always the possibility that 
the pathogen will mutate back to its virulent form and cause disease. Therefore, 
attenuated vaccines are not recommended for the elderly or for individuals who are 
immune compromised. Another disadvantage to live attenuated vaccines is their shelf 
life. Live vaccines usually need to be refrigerated to remain potent, making them sub-
optimal for shipment purposes and for administering them in poorly developed nations. 
Lastly, attenuated vaccines are challenging to make against bacteria due to the greater 
amount of genes compared to viruses. Bacteria with a greater number of genes have a 
higher risk of reverting to their virulent form.  
An inactivated vaccine contains the pathogen, which is killed via heat, radiation, 
or chemicals. The benefits of this type of vaccine are that that pathogen cannot revert 
back to its virulent form; also, inactivated vaccines typically do not need to be 
refrigerated. However, one disadvantage is that inactivated vaccines do not elicit as 
strong of an immune response and therefore a greater dosage and booster shots are often 
needed to maintain immunity. Again, in developing nations this may pose a problem if 
access to healthcare is limited.  
 Subunit vaccines do not contain the entire pathogen. Instead, only an antigenic 
fragment of the pathogen is used. The benefit to this type of vaccine is that there is a 
smaller likelihood of adverse side effects. The major disadvantage of subunit vaccines is 
the difficulty in production – identifying and characterizing the antigen can be tedious 
and challenging to produce in large quantities. Furthermore, there is always the 
possibility that the virus or bacteria can mutate and change the antigen target; in this case, 
the subunit vaccine would confer no protection to the mutated pathogen.  
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Another type of vaccine is a toxoid vaccine. A toxoid is a bacterial toxin that has 
been inactivated by heat or chemicals, yet, still maintains it immunogenicity. These 
vaccines target the illness causes toxins produced by some bacteria. An immune response 
is developed against the harmless toxoid. Therefore, if the individual comes in contact 
with the toxin, antibody opsonization will occur, rendering the toxin ineffective. The 
disadvantage is that not all bacteria release toxins and the vaccine will not stop the 
colonization of the bacteria.   
If a bacterium has a polysaccharide capsule, a conjugate vaccine can be created. 
However, if a bacterium is nontypeable and lacks a polysaccharide capsule, another 
antigen source is required. In this case, a protein or peptide based vaccine can be utilized. 
The protein/peptide target in a protein-based vaccine must be surface exposed and 
conserved among strains in order to work effectively and confer broad protection.  
Lastly, there are DNA and recombinant vector vaccines. DNA vaccines contain 
the pathogens genes that encode for highly antigenic epitopes. When the gene is 
introduced, some cells will uptake the genetic material and produce the pathogen’s 
antigenic molecule on their cell surface, stimulating the immune response and creating 
antibodies for that antigen. The benefit of this type of vaccine is that since the pathogen is 
not present, there is no possibility of conferring the disease to the individual through the 
vaccine. The disadvantage of DNA vaccines is that they are still in the beginning phases 
of development. Recombinant vector vaccines resemble DNA vaccines except an 
attenuated virus or bacteria are used to introduce the gene into the cell.  
 Currently, there are no vaccines for protection against NTHi or M. cat, and only a 
species-specific vaccine for protection against S. pneumo (PCV-13 which contains 13 
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pathogenic strains of S. pneumo). An optimal protein vaccine would include protein(s) 
from NTHi that is both well conserved across diverse NTHi species and also surface 
exposed. The protein should also be able to elicit an immune response and bactericidal 
antibodies in humans. One of the leading vaccine candidates in NTHi is the 
peptidoglycan-associated lipoprotein (PAL) P6, which fulfills the above criteria for being 
an excellent vaccine candidate.    
There are five major outer membrane proteins expressed by NTHi: P1, P2, P4, P5, 
and P6 (47,000 Da, 39,000 Da, 30,000 Da, 37,000 Da, and 16,000 Da respectively) [8, 
37, 56-61]. However, the proteins P1, P2, and P5 are heterogeneous (not conserved) 
between species. Conversely, P4 and P6 are highly conserved among strains and 
antigenically stable [8, 37, 56, 59, 62-64]. Further, the P6 protein elicits a strong 
bactericidal antibody response [64, 65]. The gene encoding for P6 has been found in all 
strains of Haemophilus influenzae (known as of 2006) [66], and its nucleotide homology 
is 97% analogous and the amino acid sequence is 100% analogous between strains [66]. 
P6 was discovered in the mid-1980s [67]. It is, by weight, approximately 1-5% of the 
total amount of surface expressed proteins produced by NTHi [61, 68].  
Although the function of P6 is still unclear, it is thought to play a structural role 
by increasing the integrity of the outer membrane [58]. In Escherichia coli (E. coli), P6’s 
homologue, Pal, has been shown to interact with other proteins in a complex web that 
tethers together the outer membrane, peptidoglycan, and inner membrane, supposedly to 
enhance stability/integrity of the cell [66, 69-71]. The proteins that participate in this web 
are often referred to as the Tol-Pal complex. Homologues of the Tol-Pal complex have 
been found in NTHi and therefore, presumably, perform a similar task in NTHi [66, 72-
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75]. It has also been shown that, in humans, P6 can act as a mediator molecule, activating 
NF-κ through a TLR (Toll-like receptor), which results in the release of proinflammatory 
cytokines [76-79]. Additionally, P6 can stimulate the production of mucin. The effects 
seen by P6 are akin to other PAL proteins of similar bacteria [66, 80, 81]. Finally, Pal of 
E. coli and several other bacteria have been implicated in the onset of Gram-negative 
sepsis via its release from the bacterial cell [82-84].  
Anti-P6 antibodies have been found in sera, middle ear effusion, breast milk, and 
nasopharyngeal secretions [37, 58, 85, 86]. Non-otitis-prone children (i.e., children who 
get <1 ear infection per year) show higher antibody levels to P6 compared to otitis prone 
children, suggesting that the presence of P6 antibody may be protective [8, 58]. Also, 
normal human serum that has been depleted of P6 antibodies via column chromatography 
shows a reduction in bactericidal activity against NTHi [57, 87]. These findings 
demonstrate that the human immune system is able to “identify” P6 as an antigen and 
initiate an immune response and subsequent antibody production against P6 from NTHi. 
Although not definitive evidence, these findings support the idea that a vaccine 
containing P6 would be protective against infection by NTHi.  
Although NTHi does not naturally colonize in rats, mice, or chinchillas, all three 
have been used in animal models to better understand OM [66, 88]. In the animal models, 
antibodies to P6 were shown to be protective against colonization by NTHi [37, 64, 66, 
89]. Additionally, systemic and mucosal immunization with P6 produces a robust 
antibody response in animals [8]. Mucosal immunization with P6 also showed increase 
clearance of NTHi in an infant rat model and protection from OM in a chinchilla model. 
Immunization with the P6 protein in several animal models results in the production of 
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bactericidal antibodies to NTHi [59]. Lastly, in a mouse model, using different MHC 
haplotype mice, it was shown that P6 could act as a vaccine antigen. Vaccination with P6 
yielded a pronounced and sustained primary antibody response in those mice and a 
secondary antibody response after a second subimmunogenic dose of whole NTHi. The 
results from these animal models, in light of the findings in humans described above, all 
point to P6 being a good vaccine candidate for broad range of coverage and protection 
against NTHi.  
 
Dual orientation and surface exposure 
 P6 was initially thought to be a transmembrane protein, allowing it to interact 
with molecules on both sides of the outer membrane. The protein was shown to be non-
covalently bound to the peptidoglycan layer inside the cell and was also shown to interact 
with antibodies on the cell surface [37, 90-92]. However, through structural, 
computational, and biochemical studies, our lab showed that P6 was not a transmembrane 
protein but existed in a dual orientation; that is, a subpopulation of P6 faced out toward 
the extracellular space and a second subpopulation of P6 faced in towards the periplasm 
(See Figure 2.0) [90, 93]. P6 is an outer membrane lipoprotein and therefore contains an 
N-terminal lipid moiety that allows the protein to tether itself to either the inner or outer 
leaflet of the outer membrane [60]. 
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Figure 2.0: Schematic describing the dual orientation of P6 in NTHi (Protein Data Bank 
ID 2AIZ). There are two populations of P6, inserted into the inner and outer leaflets of 
the outer membrane via an N-terminal lipid moiety (orange circle). 
 
 To better elucidate the two populations of P6, our lab employed a biotinylation 
labeling technique. In the experiment, a biotin label was added to whole NTHi cells, 
allowing it to bind covalently to all surface exposed proteins (the biotin molecule we used 
could not penetrate the cellular membrane unless perforated). The excess biotin was 
quenched with primary amines and the whole NTHi cells were lysed via sonication to 
“release” the biotinylated (extracellular) and non-biotinylated (intracellular) proteins; the 
two populations of P6 were separated via a streptavidin column and then detected on an 
immunoblot (with anti-P6). The results from these experiments demonstrated that the 
population of surface exposed P6 was far lower than the population of internal P6. We 
showed that, in general, less than 25% of the total P6 population was surface exposed 
(data not published; see Results section). In addition, we employed flow cytometry and 
confocal microscopy to show that P6 is surface exposed in an “all or nothing” manner. In 
other words, some NTHi cells are covered with surface exposed P6 (allowing for anti-P6 
detection and labeling of the cell surface) while other NTHi cells contain little or no 
detectable surface P6. Flow cytometric analysis allowed us to demonstrate that, in 
  17 
 
general, less than 5% of given population of NTHi cells contain detectable surface P6. 
These findings showed, for the first time, that a bacterial lipoprotein could exhibit two 
unique orientations in an “all or nothing” manner.   
However, all of the experiments described above were conducted using a single 
strain of NTHi: strain 86-023 (WT). Additionally, all of the cells tested were grown under 
aerobic conditions and neutral pH. Therefore, there was a pressing need to determine 
whether or not P6 dual orientation existed in other NTHi strains and under more 
physiologically relevant pH and oxygen conditions.   
 The aim of this work was to determine the role (if any) of pH and oxygen 
availability in P6 surface expression levels, and to assess P6 dual orientation in multiple 
clinical strains of NTHi. We discovered, using flow cytometry, confocal microscopy, and 
a biotinylation labeling technique, that P6 is dual oriented in multiple clinical strains of 
NTHi and levels of P6 surface exposure is not dependent on oxygen availability and only 
slightly dependent on the pH of the NTHi growth media. These results allow us to keep 












 NTHi cultures were acquired from Rochester General Hospital via patient 
samples (extracted from nasopharyngeal or middle ear fluid samples). The bacteria were 
grown on chocolate agar plates and cultures were grown in sterile brain-heart infusion 
(BHI) media supplemented with 20 µg/ml NAD and 10 µg/ml hemin. The NTHi was 
grown, shaking at 200 rpm at 37˚C until they reached an optical density at 490 nm 
(OD490) of 0.65-0.85. To prepare glycerol stocks, 900 µL of bacteria was mixed with 100 
µL of sterile 80% glycerol, flash frozen in liquid nitrogen, and stored at -80˚C. For 
further sample preparation, the cells were pelleted gently (5000xg) and washed in PBS. 
 
NTHi Cultures – pH and Oxygen Experiments 
 The NTHi bacteria were cultured on chocolate agar plates as described above, but 
the liquid culture conditions were modified for the pH and oxygen experiments. For the 
pH experiments, the NTHi were incubated in BHI media (supplemented with NAD and 
hemin) with adjusted pH values using sodium hydroxide and hydrochloric acid. The cells 
were then cultured as described above. For the microaerophilic studies, the NTHi cells 
were grown in a Thermo Scientific HERAcell 150i CO2 incubator at 37° C, at 5% CO2 
and 1-3% O2 levels until the OD490 reached approximately 0.8-1.0 (~109 cfu). For the 
anaerobic studies, the NTHi cells were grown in an Anaerobe Systems AS-580 anaerobe 
chamber at 37° C, at 0% O2 levels until the OD490 reached approximately 0.8-1.0 (~109 
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cfu). The OD’s were collected on a Beckman Coulter DU730 UV/Vis spectrophotometer 
for all pH media adjusted experiments and on a BIO-RAD SmartSpec Plus 
spectrophotometer for both the microaerophilic and anaerobic experiments.  
  
Surface Protein Biotinylation Experiment 
 For the surface biotinylation experiments, 10 mL of NTHi cultures were grown as 
described above. The bacteria were pelleted at 5,000 xg for 8 minutes in a 50 mL Falcon 
tube. The pellet was washed (5000 xg) in 10 mL of phosphate buffered saline (PBS) 
several times and resuspended in PBS to a final volume of 1 mL. A 25 mg/mL stock of 
NHS-LC-LC-Biotin was prepared in dimethyl sulfoxide (DSMO) right before addition to 
the bacteria. 20 µL of the NHS-LC-LC-Biotin stock was allowed to incubate with the 
NTHi cells for 30-40 minutes (such that the biotin linker could conjugate to surface 
proteins via exposed lysine/arginine residues). The excess NHS-LC-LC-Biotin was 
quenched with 400 µL of quenching solution (100 mM glycine in PBS) and washed 
several times with 1x Tris-buffered saline (TBS) to remove all excess biotin. The bacteria 
were brought to a final volume of 10 mL in TBS at which point 30 µL of Triton X-100 
was added to the cells to aid in lysis.  
 The cells were then lysed via sonication using a Qsonica XL-2000 sonicator in an 
ice-bath (setting 3) for 15 seconds on and 45 seconds off, for 20 cycles. The lysed 
bacteria were centrifuged at maximum speed (10,000 rpm) for 10 minutes in a Beckman 
and Coulter Allegra 25R centrifuge. The supernatant containing both the biotinylated and 
nonbiotinylated proteins was transferred to an Amicon concentration tube (10,000 
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MWCO). The protein was then concentrated down at 5,000 xg until the solution was 
approximately 500 µL.  
 To separate the biotinylated surface proteins from the nonbiotinylated internal 
proteins, 500 µL of the NeutrAvidin slurry (Pierce cell surface protein isolation kit 
89881) was washed in PBS and then incubated with the concentrated cell lysate for 60 
minutes with end-over-end mixing at room temperature. The cell lysate/NeutrAvidin 
mixture was added to a spin column (Pierce), and the flow-through (containing unbound 
nonbiotinylated proteins) was collected by spinning the beads at 1,000 xg for 1 minute. 
The flow-through was transferred to a microcentrifuge tube and mixed with an equal 
amount of 2x sample buffer (RECIPE). The NeutrAvidin beads were washed 3 times with 
500 µL PBS before the column was capped. 500 µL of 2x sample buffer was added to 
beads (in the capped column) and allowed to incubate in boiling water for 10 minutes. 
After boiling, the flow-through (containing the eluted biotinylated proteins) was collected 
and an equal amount of 1x TBS was added to mixture. Both the nonbiotinylated and 
biotinylated samples were stored at -20˚C or run on an SDS-PAGE gel immediately for 
analysis. 
 
Surface Protein Biotinylation Experiment: Microaerophilic and Anaerobic Conditions 
 The nonbiotinylated and biotinylated samples were prepared as described above, 
with the following modifications. The NTHi were cultured in the microaerophilic or 
anaerobic chambers. For the microaerophilic experiments, all subsequent steps were 
performed under normal oxygen conditions. For the anaerobic experiments, the cells 
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were kept in the anaerobic chamber through the biotinylation step, at which point, the 
cells were removed from the chamber. 
 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 For the biotinylation experiments, both the biotinylated and nonbiotinylated 
samples were analyzed and quantified via SDS-PAGE. Prior to the gel, both samples 
were centrifuged at 5,000 xg for 10 minutes to remove all large particles. The SDS-
PAGE gel was prepared using standard recipes for the separating gel (3.27 mL of 30% 
acrylamide/bis-acrylamide, 3.33 mL Tris/SDS (Tris/SDS solution: 182 g Tris base, 1.5 g 
SDS, pH 8.0), 1.38 mL nanopure water, 2.12 mL 50% glycerol, 100 µL 10% ammonium 
persulfate (APS), and 10 µL tetramethylethylenediamine (TEMED)) and the stacking gel 
(405 µL 30% acrylamide/bis-acrylamide, 775 µL Tris/SDS, 1.95 mL nanopure water, 20 
µL 10% APS, and 5 µL TEMED). The separating gel was added to the glass gel plates 
(Biorad) and allowed to cool/harden before the addition of the stacking gel and comb (10 
samples). The gel apparatus was prepared with cathode buffer (10x cathode buffer: 60.6 g 
Tris base, 89.6 g Tricine, 5 g SDS, and 500 mL nanopure water) in the center of the 
electrophoresis tank and anode buffer on the outside of gel plates (10x anode buffer: 
121.1g of Tris base and 500 mL of nanopure water that had been pH adjusted to 8.9 using 
12 M hydrochloric acid).   
 The biotinylated and nonbiotinylated samples were loaded into the gel (14 µL), 
alongside 5 µL of Kaleidoscope protein ladder (Biorad). The samples were separated on 
the gel using an external voltage source (120-155 V).   





Semi-Dry Protein Transfer 
 To transfer the protein samples to a nitrocellulose membrane (for 
immunodetection), we placed the gel in transfer buffer (5.82 g tris base, 2.93 g glycine, 
200 mL methanol, and 800 mL of nanopure water). The nitrocellulose membrane (0.45 
micron, 8 cm x 8 cm) and 2 western blotting filter papers (8 cm x 10.5 cm) were also 
soaked in transfer buffer for 5 minutes. We placed the pre-wet filter paper, pre-wet 
nitrocellulose membrane, equilibrated gel, and second pre-wet filter paper (in that order) 
on the bottom plate of the Biorad Trans-Blot SD semi-dry transfer cell. After the filter 
paper was smoothed to remove air bubbles, the stainless steel cathode and lid were 
secured and the proteins were transferred to the membrane for 15 minutes (15 V).  
 
Western Blot Protocol 
The transferred nitrocellulose membrane was incubated in 15 mL of 5% milk in 
1x TBS for 30 minutes (rocking). Next, the membrane was incubated in a primary 
antibody solution (50 µL of primary antibody (1°), monoclonal antibody 7F3 (anti-P6), in 
6 ml of 1% milk in TBST (100 mL 1x TBS, 50 µL TWEEN-20, 1 g powdered milk)) 
rocking at room temperature for 1 hour. The membrane was washed twice for 15 minutes 
with 1x TBST. Then, the membrane was incubated in a secondary antibody solution (2 
µL of secondary antibody (2°), goat anti-mouse IgG-h+I HRP conjugate (BETHYL 
laboratories) in 6 ml of 1% milk in TBST) for 1 hour, rocking, at room temperature. After 
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three washes with TBST (10 minutes each) and two additional washes with TBS (5 
minutes each), the proteins in the membrane were detected using Lumiglo reserve HRP 
chemiluminescent substrate (Biorad: 2 parts chemiluminescent substrate A + 1 part 
chemiluminescent substrate B). The proteins were detected on a Biorad BioDoc system 
using the chemiluminescent setting and quantified using the Quantity One software.  
 
Confocal Microscopy 
 The NTHi cells were grown as described above. The bacteria were washed 
several times with PBS (5,000 xg for 2 minutes) and then resuspended in 1% bovine 
serum albumin (BSA)/PBS solution. Next, the cells were incubated in primary antibody 
(monoclonal antibodies 3B9 and 7F3: 12.5 µL; monoclonal antibody 4G4: 2 µL; anti-P6 
polyclonal antibody: 1.5 µL) diluted in 250 µL BSA/PBS for one hour at room 
temperature (rocking). After the primary incubation, the cells were washed three times in 
BSA/PBS then resuspended in secondary antibody (Goat anti-mouse conjugated to either 
Alexa Fluor 488 (excitation 496 nm, emission 519 nm) or Alexa Fluor 647 (excitation 
650 nm, emission 665 nm)) diluted in 250 µL of BSA/PBS for 45 minutes. After three 
additional washes in BSA/PBS, the cells were either fixed in paraformaldehyde (4% for 
20 minutes) or incubated with 15 µL of BODIPY vancomycin (excitation 485 nm, 
emission 519 nm) diluted in 250 µL of BSA/PBS for 45 minutes and then fixed. After 
three final washes in BSA/PBS solution the cells were stored at 4˚C (in the dark). Just 
before the confocal images were collected, the cells were gently pelleted (5000 xg) and 
resuspended in 50 µL of BSA/PBS.  
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 Slides were prepared in a biosafety II cabinet in the confocal laboratory. Between 
3 and 5 µL of cells were added to the glass microscope slides and a glass coverslip was 
place on top of the sample. Clear nail polish was applied to the perimeter of the coverslip 
to seal it to the slide. AmScope immersion oil was placed on the objective lens to 
increase resolution of the images collected by the Leica TCS SP5 II AOBS filterfree 
tunable spectral confocal research microscope with resonant scanner 
and hybrid detectors. Images were collected in collaboration with the RIT confocal 
technician, Evan Darling or Steven Wilburt. All images were analyzed and prepared 
using the Leica Las AF Lite software.  
 
Flow Cytometry 
 NTHi samples were prepared as described above in the confocal experiment, 
except the final samples were resuspended in 200-300 µL of BSA/PBS. The samples 
were analyzed on an LSR II flow cytometer (BD Biosciences) at Rochester General 
Hospital Research Institute (RGHRI). All gating was performed by an expert in flow 
cytometry, Dr. Naveen Surendran (RGHRI).   
  
Fluorescence-Activated Cell Sorting (FACS) Protocol 
NTHi samples were prepared as described above in the flow cytometry 
experiment, except the cell samples were not fixed in paraformaldehyde and were not 
labeled with BODIPDY-vancomycin. The samples were analyzed and sorted on a 
FACSaria II instrument at the University of Rochester. The P6 labeled and non-labeled 
cells were sorted and collected in two collection tubes. Both samples were used to 
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inoculate an NTHi growth in 10 mL of BHI (supplemented with hemin and NAD) using 
~300 µL of cells. The bacteria were then grown to an OD490 of approximately 0.80 and 
prepared as described above (i.e., labeled with anti-P6 and Goat anti-mouse AlexaFluor 
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3. Results  
 
Total P6 Quantification (NTHi Strains) 
 
Total P6 quantification (inner and outer leaflet P6 in NTHi) was performed to estimate 
the variance in total P6 expression across multiple NTHi strains. Our findings suggest 
that although strain 86-028 (WT) exhibits the greatest amount of total P6 expression, the 
amount of total P6 expression is relatively constant among the tested NTHi strains.  
 
Strain	   Trial	  A	  (%)	   Trial	  B	  (%)	   Average	  (%)	  
86-028 (WT)	   27	   24	   25.5	  
06-02-022 (Phoenix)	   21	   18	   19.5	  
06-02-041 (Sphinx)	   17	   16	   16.5	  
07-03-066 (Unicorn)	   15	   15	   15.0	  
02-122 AOM1 (Dragon)	   12	   14	   13.0	  
06-02-042 (Minotaur)	   8	   13	   10.5	  
Table 1.0: Detection of total P6 in different strains of NTHi. Experiments were 
performed to determine the total amount of P6 expression (in both orientations) in six 




Figure 3.0: Detection of P6 in different strains of NTHi. Experiments were performed to 
determine the total amount of P6 expression (in both orientations) in six different strains 
of NTHi. From left to right the strains are 86-028 (WT), 06-02-022 (Phoenix), 06-02-041 
(Sphinx), 07-03-066 (Unicorn), 02-122 AOM1 (Dragon), and 06-02-042 (Minotaur). 




                 WT     Phoenix     Sphinx    Unicorn    Dragon   Minotaur  
                 WT       Phoenix     Sphinx     Unicorn    Dragon    Minotaur  
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Biotinylation of Surface P6 in Multiple NTHi Strains   
 
We employed a biotinylation labeling experiment to estimate the amount of surface and 
inner P6 in eight different clinical NTHi strains. In strain 02-122 AOM1 (Dragon), the 
average non-biotinylated (inward facing) to biotinylated (surface) P6 ratio 87:13 ± 5%. 
The strain with the least amount of surface P6 was strain 13-02-538 V3 NWB 
(Manticore), which had an average non-biotinylated to biotinylated P6 ratio of 96:4	 ± 
1%. Strains 13-02-554 V1 NW (Pegasus) and 06-02-041 (Sphinx) had the greatest 
amount of measured surface P6 with average non-biotinylated to biotinylated ratios of 
64:36	 and 65:35, respectively. The non-biotinylated: biotinylated (inner: surface) P6 





NTHi strain 02-122 AOM1 (Dragon)   
 
	   02-­‐122	  AOM	  1	  (Dragon)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   81	   19	  
2	   B	   93	   7	  
3	   C	   95	   5	  
4	   D	   90	   10	  
5	   E	   83	   17	  
6	   F	   83	   17	  
7	   G	   87	   13	  
	   Average	   87	   13	  
	   Standard	  Dev.	  	   5	   5	  
Table 1.1: Quantification of the two P6 populations in NTHi strain 02-122 AOM1 
(Dragon). Immunoblotting analysis provided the ratio of internal non-biotinylated P6 to 













Figure 3.1: Detection of the two P6 populations in NTHi strain 02-122 AOM1 (Dragon). 
P6 was detected via immunoblot with P6 monoclonal antibody 7F3. In all of the 
immunoblots, the non-biotinylated sample was loaded in the left lane and the biotinylated 
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Figure 3.2: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 
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NTHi strain 13-02-538 V3 NWB (Manticore)   
 
 








1	   A	   95	   5	  
2	   B	   97	   3	  
	   Average	   96	   4	  
	   Standard	  Dev.	  	   1	   1	  
Table 1.2: Quantification of the two P6 populations in NTHi strain 13-02-538 V3 NWB 
(Manticore). Immunoblotting analysis provided the ratio of internal non-biotinylated P6 











Figure 3.3: Detection of the two P6 populations in NTHi strain 13-02-538 V3 NWB 
(Manticore). P6 was detected via immunoblot with P6 monoclonal antibody 7F3. In all of 
the immunoblots, the non-biotinylated sample was loaded in the left lane and the 
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Figure 3.4: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 
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NTHi strain 06-02-042 (Minotaur) 
 
	   06-­‐02-­‐042	  (Minotaur)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   69	   31	  
2	   B	   70	   30	  
3	   C	   63	   37	  
4	   D	   78	   22	  
5	   E	   71	   29	  
6	   F	   70	   30	  
	   Average	   70	   30	  
	   Standard	  Dev.	  	   4	   4	  
Table 1.3: Quantification of the two P6 populations in NTHi strain 06-02-042 
(Minotaur). Immunoblotting analysis provided the ratio of internal non-biotinylated P6 to 








Figure 3.5: Detection of the two P6 populations in NTHi strain 06-02-042 (Minotaur). 
P6 was detected via immunoblot with P6 monoclonal antibody 7F3. In all of the 
immunoblots, the non-biotinylated sample was loaded in the left lane and the biotinylated 
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Figure 3.6: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 
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NTHi strain 13-02-554 V1 NW (Pegasus)   
 
	   13-­‐02-­‐554	  V1	  NW	  (Pegasus)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   62	   38	  
2	   B	   59	   41	  
3	   C	   60	   40	  
4	   D	   58	   42	  
5	   E	   75	   25	  
6	   F	   67	   33	  
	   Average	   64	   37	  
	   Standard	  Dev.	  	   6	   6	  
Table 1.4: Quantification of the two P6 populations in NTHi strain 13-02-554 V1 NW 
(Pegasus). Immunoblotting analysis provided the ratio of internal non-biotinylated P6 to 






Figure 3.7: Detection of the two P6 populations in NTHi strain 13-02-554 V1 NW 
(Pegasus). P6 was detected via immunoblot with P6 monoclonal antibody 7F3. In all of 
the immunoblots, the non-biotinylated sample was loaded in the left lane and the 
biotinylated sample was loaded in the right lane. 
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Figure 3.8: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 
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NTHi strain 06-02-022 (Phoenix) 
 
	   06-­‐02-­‐022	  (Phoenix)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
	  	   A1	   87	   13	  
	  	   A2	   80	   20	  
1	   A	  (avg)	   84	   17	  
	  	   B1	   70	   30	  
	  	   B2	   67	   33	  
2	   B	  (avg)	   69	   32	  
	  	   C1	   69	   31	  
	  	   C2	   67	   33	  
3	   C	  (avg)	   68	   32	  
4	   D	   89	   11	  
5	   E	   80	   20	  
6	   F	  	   87	   13	  
	   Average	   79	   21	  
	   Standard	  Dev.	  	   8	   8	  
Table 1.5: Quantification of the two P6 populations in NTHi strain 06-02-022 (Phoenix). 






Figure 3.9: Detection of the two P6 populations in NTHi strain 06-02-022 (Phoenix). P6 
was detected via immunoblot with P6 monoclonal antibody 7F3. In all of the 
immunoblots, the non-biotinylated sample was loaded in the left lane and the biotinylated 
sample was loaded in the right lane. 
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Figure 3.10: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 
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NTHi strain 06-02-041 (Sphinx) 
 
	   06-­‐02-­‐041	  (Sphinx)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   66	   34	  
2	   B	   64	   36	  
	   Average	   65	   35	  
	   Standard	  Dev.	  	   1	   1	  
Table 1.6: Quantification of the two P6 populations in NTHi strain 06-02-041 (Sphinx). 











Figure 3.11: Detection of the two P6 populations in NTHi strain 06-02-041 (Sphinx). P6 
was detected via immunoblot with P6 monoclonal antibody 7F3. In all of the 
immunoblots, the non-biotinylated sample was loaded in the left lane and the biotinylated 
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Figure 3.12: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 















1	   2	  
Non-­‐Biotinylated	  %	   66	   64	  



















06-­02-­041	  (Sphinx)	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NTHi strain 03-02-066 (Unicorn) 
 
 06-­‐03-­‐066	  (Unicorn)	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
	  	   A1	   65	   35	  
	  	   A2	   75	   25	  
1 A	  (avg)	   70	   30	  
  B1	   70	   30	  
	  	   B2	   78	   22	  
2	   B	  (avg)	   74	   26	  
3	   C	   84	   16	  
4	   D	   70	   30	  
	   Average	   75	   25	  
	   Standard	  Dev.	  	   6	   6	  
Table 1.7: Quantification of the two P6 populations in NTHi strain 06-03-066 (Unicorn). 







Figure 3.13: Detection of the two P6 populations in NTHi strain 06-03-066 (Unicorn). 
P6 was detected via immunoblot with P6 monoclonal antibody 7F3. In all of the 
immunoblots, the non-biotinylated sample was loaded in the left lane and the biotinylated 
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Figure 3.14: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 








1	   2	   3	   4	  
Non-­‐Biotinylated	  %	   70	   74	   84	   70	  



















06-­03-­066	  (Unicorn)	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NTHi strain 86-028 (WT) 
 
 86-­‐028	  (WT)	  




1	   A	   76	   24	  
2	   B	   94	   6	  
3	   C	   77	   23	  
4	   D	   83	   17	  
5	   E	   93	   7	  
	   Average	   85	   15	  
	   Standard	  Dev.	  	   8	   8	  
Table 1.8: Quantification of the two P6 populations in NTHi strain 86-028 (WT). 











Figure 3.15: Detection of the two P6 populations in NTHi strain 86-028 (WT). P6 was 
detected via immunoblot with P6 monoclonal antibody 7F3. In all of the immunoblots, 
the non-biotinylated sample was loaded in the left lane and the biotinylated sample was 
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Figure 3.16: Graphical analysis of non-biotinylated (inner) and biotinylated (surface) P6 









1	   2	   3	   4	   5	  
Non-­‐Biotinylated	  %	   76	   94	   77	   83	   93	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Summary of average nonbiotinylated: biotinylated ratios for all tested NTHi strains 
 
 
* Strain 13-02-538 and 06-02-041 lack enough trails to produce statistically relevant error 
bars.  
 
Figure 3.17: Graphical analysis of the average non-biotinylated and biotinylated P6 

























NB	  %	   87	   96	   70	   64	   79	   65	   75	   85	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Flow Cytometric Analysis of P6 in Multiple NTHi Strains 
 
Flow cytometry experiments were performed to detect the variability of the surface P6 
population from strain to strain. In the experiments, monoclonal or polyclonal anti-P6 
antibodies were employed to bind surface P6. A secondary antibody conjugated to a 
fluorophore allowed for detection and quantification of the P6-antibody sandwich. The 
output of the flow experiments was a series of flow charts, which allowed us to estimate 
the percentage of total cells, which contained detectable surface P6. A BODIPY-
vancomycin control allowed us to differentiate between labeled P6 in whole cells (no 
vancomycin labeling) and labeled P6 in perforated or compromised cells (positive 
BODIPY-vancomycin labeling). 
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Figure 4.0: Flow cytometric analysis of surface P6 in three different NTHi strains. Cells 
were labeled with P6 antibodies (polyclonal anti-P6) and Alexa Fluor® 647 (APC-A); 
BODIPY-vancomycin labeled the peptidoglycan of compromised cells. Control #1 shows 
whole cells only. Control #2 shows whole cells labeled with secondary antibody (Alexa 
Fluor® 647) only. Control #3 shows P6 labeling (y-axis) (no BODIPY-vancomycin). In 
the complete experiment (#4), surface P6 is labeled (y-axis, Q1), peptidoglycan is labeled 
(x-axis, Q3), or both are labeled (Q2). The percentages of labeled population are depicted 
in the corners of the quadrants. 




                             
Figure 4.1: Flow cytometric analysis of surface P6 in three different NTHi strains. Cells 
were labeled with P6 antibodies (polyclonal anti-P6) and Alexa Fluor® 647 (APC-A); 
BODIPY-vancomycin labeled the peptidoglycan of compromised cells. Control #1 shows 
whole cells only. Control #2 shows whole cells labeled with secondary antibody (Alexa 
Fluor® 647) only. Control #3 shows P6 labeling (y-axis) (no BODIPY-vancomycin). In 
the complete experiment (#4), surface P6 is labeled (y-axis, Q1), peptidoglycan is labeled 
(x-axis, Q3), or both are labeled (Q2). The percentages of labeled population are depicted 






  48 
 
 
	   Surface	  P6	  Expression	  (%)	  
Strains	  
Labeled	  without	  vancomycin	  
control	  (may	  include	  
dead/compromised	  cells)	  
Labeled	  with	  vancomycin	  
control	  to	  exclude	  
dead/compromised	  cells	  	  
86-028 (WT) 18.36	   16.90	  
07-03-066 (Unicorn) 9.38	   5.23	  
06-02-041 (Sphinx) 11.16	   5.84	  
06-02-022 (Phoenix) 31.06	   17.40	  
06-02-042 (Minotaur) 9.66	   11.60	  
02-122 AOM1 (Dragon) 13.38	   2.59	  
Table 2.0: Quantification of surface P6 in six NTHi strains using flow cytometry. Flow 
cytometric analysis allowed us to estimate the percentage of total NTHi cells with 
detectable surface P6. The left column shows the percentage of cells labeled with surface 
P6, but without the vancomycin control experiment; therefore, these values may include 
labeled dead/compromised cells. The right column shows the percentage of cells labeled 
with surface P6, but since we also employed a BODIPY-vancomycin control, we were 
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Total P6 Quantification (pH 5-9 Experiment) 
 
We have shown that P6 is localized to both on the inner and outer leaflet of the outer 
membrane of NTHi. However, in these total P6 quantification experiments, we sought to 
measure the amount of total P6 (from both leaflets of the outer membrane). Here, we 
demonstrated that the amount of total P6 expressed in NTHi is relatively consistent when 




Figure 5.0: Detection of P6 in NTHi cultured at different pH values. NTHi cells labeled 
with 7F3/secondary HRP and detected via immunoblot. Both experiments were 
conducted using NTHi strain 86-028 (WT). Experiments were performed to determine 
the total amount of P6 expression (in both orientations) under the pH condition of 5-9.  
Two trials of the experiment were conducted (1 and 2) with two immunoblots prepared 
for each trial (a and b).  
 
Exp. 1a 
Exp. 2b Exp. 2a 
Exp. 1b 
pH:   5          6           7          8          9  
pH:        5          6         7         8          9  
pH:         5         6         7         8         9  
pH:          5         6        7        8         9  
































5	   20 20 20	   21 18 20	   20	   0.25	  
6	   28 22 25	   19 26 23	   24	   1.25	  
7	   28 24 26	   24 25 25	   25	   0.75	  
8	   17 30 24	   24 24 24	   24	   0.25	  
9	   7 4 6	   11 8 10	   8	   2	  
Table 3.0: Total quantification of P6 in NTHi expressed at different pH values. 
Immunoblotting analysis provides the ratios of total P6 expressed in NTHi when cultured 
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P6 Populations: pH 7 
 
We also performed biotinylation experiments to estimate the nonbiotinylated (inner) to 
biotinylated (surface) P6 ratios in NTHi cultured under variable pH’s. We chose to assess 
the P6 ratios in NTHi cultured at pH 7, 7.5, 8, and 8.5, since these were the most 
physiologically relevant pH values (for the nose and inner ear). In summary, NTHi grown 
at pH 7 and 7.5 have similar amounts of surface P6 and NTHi grown at pH 8 and 8.5 






Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   71	   29	  
2	   B	   90	   10	  
3	   C	   85	   15	  
4	   D	   66	   34	  
5	   E	   59	   41	  
6	   F	   85	   15	  
7	   G	   65	   35	  
8	   H	   85	   15	  
	   Average	   76	   24	  
	   Standard	  Dev.	  	   11	   11	  
Table 3.1: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 
(internal) and biotinylated (surface) P6 populations in NTHi cultured at pH 7.  
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Figure 5.1: Detection of P6 in NTHi cultured at pH 7. All experiments were conducted 
on NTHi strain 86-028 (WT), and all immunoblots were detected using monoclonal P6 
antibody 7F3. Left lanes contained nonbiotinylated (internal) P6 and right lanes contained 




Figure 5.2: Graphical analysis of the data collected in the biotinylation experiments for 
NTHi grown at pH 7. 
1	   2	   3	   4	   5	   6	   7	   8	  
Non-­‐Biotinylated	  %	   71	   90	   85	   66	   59	   85	   65	   85	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P6 Populations: pH 7.5 
 
pH	  7.5	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   65	   35	  
2	   B	   77	   23	  
3	   C	   87	   13	  
	   Average	   76	   24	  
	   Standard	  Dev.	  	   9	   9	  
Table 3.2: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 
(internal) and biotinylated (surface) P6 populations in NTHi cultured at pH 75. 
 
 
Figure 5.3: Detection of P6 in NTHi cultured at pH 7.5. All experiments were conducted 
on NTHi strain 86-028 (WT), and all immunoblots were detected using monoclonal P6 
antibody 7F3. Left lanes contained nonbiotinylated (internal) P6 and right lanes contained 
biotinylated (surface) P6. 
 
 
Figure 5.4: Graphical analysis of the data collected in the biotinylation experiments for 
NTHi grown at pH 7.5.  
 
1	   2	   3	  
Non-­‐Biotinylated	  %	   65	   77	   87	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Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   95	   5	  
2	   B	   76	   24	  
3	   C	   96	   4	  
4	   D	   65	   35	  
5	   E	   84	   16	  
	   Average	   83	   17	  
	   Standard	  Dev.	  	   12	   12	  
Table 3.3: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 








Figure 5.5: Detection of P6 in NTHi cultured at pH 8. All experiments were conducted 
on NTHi strain 86-028 (WT), and all immunoblots were detected using monoclonal P6 
antibody 7F3. Left lanes contained nonbiotinylated (internal) P6 and right lanes contained 
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Figure 5.6: Graphical analysis of the data collected in the biotinylation experiments for 
NTHi grown at pH 8. 
 
 





Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   76	   24	  
2	   B	   95	   5	  
3	   C	   92	   8	  
4	   D	   64	   36	  
	   Average	   82	   18	  
	   Standard	  Dev.	  	   13	   13	  
Table 3.4: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 




1	   2	   3	   4	   5	  
Non-­‐Biotinylated	  %	   95	   76	   96	   65	   84	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Figure 5.7: Detection of P6 in NTHi cultured at pH 8.5. All experiments were conducted 
on NTHi strain 86-028 (WT), and all immunoblots were detected using monoclonal P6 
antibody 7F3. Left lanes contained nonbiotinylated (internal) P6 and right lanes contained 
biotinylated (surface) P6. 
 
 
Figure 5.8: Graphical analysis of the data collected in the biotinylation experiments for 
NTHi grown at pH 8.5. 
 
1	   2	   3	   4	  
Non-­‐Biotinylated	  %	   76	   95	   92	   64	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Summary of Nonbiotinylated: Biotinylated P6 Ratios in NTHi Cultured at Several 




Figure 5.9: Graphical analysis of the average non-biotinylated and biotinylated P6 








pH	  7	   pH	  7.5	   pH	  8	   pH	  8.5	  
Non-­‐Biotinylated	  %	   76	   76	   83	   82	  



















P6	  Populations	  pH	  7-­8.5	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Flow Cytometric Analysis of NTHi Grown in pH Adjusted Media 
 
Flow cytometry experiments were performed to detect the variability of the surface P6 
population when NTHi was cultured at different pH values. In the experiments, 
monoclonal or polyclonal anti-P6 antibodies were employed to bind surface P6. A 
secondary antibody conjugated to a fluorophore allowed for detection and quantification 
of the P6-antibody sandwich. The output of the flow experiments was a series of flow 
charts that allowed us to estimate the percentage of total cells, which contained detectable 
surface P6. A BODIPY-vancomycin control allowed us to differentiate between labeled 
P6 in whole cells (no vancomycin labeling) and labeled P6 in perforated or compromised 
cells (positive BODIPY-vancomycin labeling). Results suggest that NTHi contains 
greater levels of surface P6 when cultured at pH 8.0.   




Figure 6.0: Flow cytometric analysis of surface P6 in NTHi grown in pH adjusted BHI 
media (pH 7, 7.5, and 8). Cells were labeled with P6 antibodies (polyclonal anti-P6) and 
Alexa Fluor® 647 (APC-A); BODIPY-vancomycin labeled the peptidoglycan of 
compromised cells. Control #1 shows whole cells only. Control #2 shows whole cells 
labeled with secondary antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling 
(y-axis) (no BODIPY-vancomycin). In the complete experiment (#4), surface P6 is 
labeled (y-axis, Q1), peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The 
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Figure 6.1: Flow cytometric analysis of surface P6 in NTHi grown in pH adjusted BHI 
media (pH 7, 7.5, 8, and 8.5). Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and Alexa Fluor® 647 (APC-A); BODIPY-vancomycin labeled the peptidoglycan of 
compromised cells. Control #1 shows whole cells only. Control #2 shows whole cells 
labeled with secondary antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling 
(y-axis) (no BODIPY-vancomycin). In the complete experiment (#4), surface P6 is 
labeled (y-axis, Q1), peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The 
percentages of labeled population are depicted in the corners of the quadrants. 
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Flow Cytometric Analysis of NTHi Grown in pH Adjusted Media (with pH 8.5, trial 2) 
 
 



































Figure 6.2: Flow cytometric analysis of surface P6 in NTHi grown in pH adjusted BHI 
media (pH 7, 7.5, 8, and 8.5). Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and Alexa Fluor® 647 (APC-A); BODIPY-vancomycin labeled the peptidoglycan of 
compromised cells. Control #1 shows whole cells only. Control #2 shows whole cells 
labeled with secondary antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling 
(y-axis) (no BODIPY-vancomycin). In the complete experiment (#4), surface P6 is 
labeled (y-axis, Q1), peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The 
percentages of labeled population are depicted in the corners of the quadrants. 
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Figure 6.3: Flow cytometric analysis of surface P6 in NTHi grown in pH adjusted BHI 
media (pH 7, 7.5, 8, and 8.5). Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and Alexa Fluor® 647 (APC-A); BODIPY-vancomycin labeled the peptidoglycan of 
compromised cells. Control #1 shows whole cells only. Control #2 shows whole cells 
labeled with secondary antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling 
(y-axis) (no BODIPY-vancomycin). In the complete experiment (#4), surface P6 is 
labeled (y-axis, Q1), peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The 
percentages of labeled population are depicted in the corners of the quadrants. 






	   pH	  
Trial	  #	   7	   7.5	   8	   8.5	  
1	   0.4%	   3.7%	   7.7%	   n/a	  
2	   6.1%	   3.2%	   7.1%	   7.4%	  
3	   3.7%	   3.3%	   7.5%	   5.1%	  
4	   4.5%	   2.3%	   6.7%	   5.5%	  
Average	   3.7%	   3.1%	   7.3%	   6.0%	  
Standard	  
Dev.	  	  
2.1%	   0.5%	   0.4%	   1.0%	  
Table 4.0: Flow cytometric detection of surface P6 in NTHi cultured in BHI media at pH 
7, 7.5, 8, and 8.5. Values represent percentages of total NTHi cells with detectable 
surface P6. No BODIPY-vancomycin label was used, thus data may be inflated due to the 




	   pH	  
Trial	  #	   7	   7.5	   8	   8.5	  
1	   1.3	   1.7	   3.0	   n/a	  
2	   4.2	   5.8	   7.0	   8.5	  
3	   1.7	   0.4	   2.4	   3.3	  
4	   0.6	   0.6	   2.2	   2.1	  
Average	   2.0	   2.1	   3.7	   4.6	  
Standard	  Dev.	  	   1.4	   2.2	   1.9	   2.8	  
Average	  w/o	  Trial	  #2	   1.2	   0.9	   2.6	   2.7	  
Standard	  Dev.	  w/o	  Trial	  #2	   0.5	   0.6	   0.4	   0.6	  
Table 4.1: Flow cytometric detection of surface P6 in NTHi cultured in BHI media at pH 
7, 7.5, 8, and 8.5. Values represent percentages of total NTHi cells with detectable 
surface P6. A BODIPY-vancomycin control was used, so values represent labeling in 
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Biotinylation of Surface P6 in NTHi Cultured Under Different Oxygen Conditions 
 
We also performed biotinylation experiments to estimate the nonbiotinylated (inner) to 
biotinylated (surface) P6 ratios in NTHi cultured under three different oxygen conditions 
(in BHI, pH ~7.5): aerobic, microaerophilic, and anaerobic. Commensal NTHi bacteria 
live predominantly in the nasal cavity of children and adults, thus exposed to aerobic 
(normal) oxygen levels. During infection, NTHi in the inner ear can experience both 
microaerophilic and perhaps anaerobic oxygen levels, due to the pinching off of the 
Eustachian tube (during OM with effusion). Our results suggest, however, that surface P6 






Detection of P6 populations: Microaerophilic Conditions 
 
	   Microaerophilic	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   66	   34	  
2	   B	   62	   38	  
3	   C	   66	   34	  
4	   D	   70	   30	  
5	   E	   73	   27	  
6	   F	   67	   33	  
7	   G	   69	   31	  
8	   H	   68	   32	  
	   Average	   68	   32	  
	   Standard	  Dev.	   3	   3	  
Table 5.0: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 
















Figure 7.0: Three individual trials of the biotinylation labeling experiment (WT strain, 
86-028) to quantify non-biotinylated (NB) P6 and biotinylated (B) P6 in NTHi cultured 
under microaerophilic conditions; detected via immunoblot (anti-P6 polyclonal 
antibody). Lane 1: ladder; lane 2: NB, trial #1; lane 3: B, trial #1; lane 4: NB, trial #2; 
lane 5: B, trial #2; lane 6: NB, trial #3; lane 7: B, trial #3. The three non-biotinylated 









Figure 7.1: Three individual trials of the biotinylation labeling experiment (WT strain, 
86-028) to quantify non-biotinylated (NB) P6 and biotinylated (B) P6 in NTHi cultured 
under microaerophilic conditions; detected via immunoblot (anti-P6 polyclonal 
antibody). Lane 1: ladder; lane 2: NB, trial #4; lane 3: B, trial #4; lane 4: NB, trial #5; 
lane 5: B, trial #5; lane 6: NB, trial #6; lane 7: B, trial #6. The three non-biotinylated 









Figure 7.3: Two individual trials of the biotinylation labeling experiment (WT strain, 86-
028) to quantify biotinylated (B, surface) P6 and nonbiotinylated (NB, internal) P6 in 
NTHi cultured under microaerophilic conditions; detected via immunoblot (anti-P6 
polyclonal antibody). Lane 1: ladder; lane 2: NB, trial #7a; lane 3: B, trial #7a; lane 4: 
NB, trial #7b; lane 5: B, trial #7b; lane 6: NB, trial #8a; lane 7: B, trial #8a; lane 8: NB, 
trial #8b; lane 9: B trial #8b. The two non-biotinylated samples were quantified as 










Figure 7.4: Graphical analysis of the data collected from the biotinylation experiments to 







1	   2	   3	   4	   5	   6	   7	   8	  
Non-­‐Biotinylated	  %	   70	   73	   67	   70	   68	   66	   62	   66	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Flow Cytometric Detection of Surface P6 in NTHi Grown Under Microaerophilic 
Conditions 
 
Flow cytometry experiments were performed to detect the variability of surface P6 levels 
in NTHi cultured (in BHI, pH ~7.5) under microaerophilic conditions. In the 
experiments, monoclonal or polyclonal anti-P6 antibodies were employed to bind surface 
P6. A secondary antibody conjugated to a fluorophore allowed for detection and 
quantification of the P6-antibody sandwich. The output of the flow experiments was a 
series of flow charts, which allowed us to estimate the percentage of total cells, which 
contained detectable surface P6. A BODIPY-vancomycin control allowed us to 
differentiate between labeled P6 in whole cells (no vancomycin labeling) and labeled P6 












































Figure 7.5:  Flow cytometric detection of surface P6 in NTHi grown under 
microaerophilic conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and AlexaFluor 488 (FITC). Control #1 shows whole cells only. Control #2 shows whole 
cells with secondary antibody only (AlexaFluor 488). Panel #3 shows whole cells labeled 
with anti-P6 and secondary antibody (Alexa Fluor 488). The percentages of labeled 



















Figure 7.6:  Flow cytometric analysis of surface P6 in NTHi grown under 
microaerophilic conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and AlexaFluor 488 (FITC). Control #1 shows whole cells only. Control #2 shows whole 
cells with secondary antibody only (AlexaFluor 488). Panel #3 shows whole cells labeled 
with anti-P6 and secondary antibody (Alexa Fluor 488). The percentages of labeled 
populations are depicted in the square inset.  
















Figure 7.7: Flow cytometric analysis of surface P6 in NTHi grown under 
microaerophilic conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and AlexaFluor® 647; BODIPY-Vancomycin labeled the peptidoglycan of compromised 
cells. Control #1 shows whole cells only. Control #2 shows labeling with secondary 
antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling (y-axis) (no 
vancomycin). In the complete experiment (#4), surface P6 is labeled (y-axis, Q1), 
peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The percentages of 
labeled populations are depicted in the corners of the quadrants. 
 
 














Figure 7.8: Flow cytometric analysis of surface P6 in NTHi grown under 
microaerophilic conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) 
and AlexaFluor 647; BODIPY-Vancomycin labeled the peptidoglycan of compromised 
cells. Control #1 shows whole cells only. Control #2 shows labeling with secondary 
antibody (Alexa Fluor® 647) only. Control #3 shows P6 labeling (y-axis) (no 
vancomycin). In the complete experiment (#4), surface P6 is labeled (y-axis, Q1), 
peptidoglycan is labeled (x-axis, Q3), or both are labeled (Q2). The percentages of 
labeled populations are depicted in the corners of the quadrants. 
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Summary of Results for Flow Cytometric Detection of Surface P6 in NTHi grown under 
Microaerophilic Conditions 
  
Microaerophilic	  (%	  labeled	  cells)	  
Trial	  #	  
Without	  control	  for	  
dead/compromised	  cells	  
With	  control	  to	  exclude	  
dead/compromised	  cells	  	  
1	   7.2	   n/a	  
2	   5.3	   n/a	  
3	   12.1	   9.6	  
4	   12.1	   3.3	  
Average	   9.2	   6.5	  
Standard	  Dev.	  	   3.0	   3.1	  
Table 5.1: Quantification of surface P6 in NTHi grown under microaerophilic conditions 
using flow cytometry. Flow cytometric analysis allowed us to estimate the percentage of 
total NTHi cells with detectable surface P6. The left column shows the percentages of 
cells labeled with surface P6, but values may include labeling of dead/uncompromised 
cells; the right column shows the percentages of cells labeled with surface P6, and a 
vancomycin control was employed so values represent labeled whole/uncompromised 





Detection of P6 Populations: Anaerobic Conditions 
 
  Anaerobic	  
Trial	  #	   Biotinylation	  Exp.	  #	   Non-­‐Biotinylated	  %	   Biotinylated	  %	  
1	   A	   65	   35	  
2	   B	   56	   44	  
3	   C	   58	   42	  
4	   D	   62	   38	  
	   Average	   60	   40	  
	   Standard	  Dev.	  	   3	   3	  
Table 6.0: A set of biotinylation experiments allowed us to estimate the nonbiotinylated 




















Figure 8.0: Three individual trials of the biotinylation labeling experiment (WT strain, 
86-028) to quantify biotinylated (B, surface) P6 and nonbiotinylated (NB, internal) P6 in 
NTHi cultured under anaerobic conditions; detected via immunoblot (anti-P6). Lane 1: 
ladder; lane 2: NB, trial #1; lane 3: B, trial #1; lane 4: NB, trial #2; lane 5: B, trial #2; 
lane 6: NB, trial #3; lane 7: B, trial #3. The three samples were quantified as 65:35%, 




Figure 8.1: One trial of the biotinylation labeling experiment (WT strain, 86-028) to 
quantify biotinylated (B, surface) P6 and nonbiotinylated (NB, internal) P6 in NTHi 
cultured under anaerobic conditions; detected via immunoblot (anti-P6). Lane 1: NB, trial 
















A, B, and C 
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Figure 8.2: Graphical analysis of the data collected from the biotinylation experiments to 









1	   2	   3	   4	  
Non-­‐Biotinylated	  %	   65	   56	   58	   62	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Flow Cytometric Analysis of Anaerobic NTHi (Trial #1) 
 
Flow cytometry experiments were performed to detect the variability of surface P6 levels 
in NTHi cultured (in BHI, pH ~7.5) under microaerophilic conditions. In the 
experiments, monoclonal or polyclonal anti-P6 antibodies were employed to bind surface 
P6. A secondary antibody conjugated to a fluorophore allowed for detection and 
quantification of the P6-antibody sandwich. The output of the flow experiments was a 
series of flow charts, which allowed us to estimate the percentage of total cells that 
contained detectable surface P6. A BODIPY-vancomycin control allowed us to 
differentiate between labeled P6 in whole cells (no vancomycin labeling) and labeled P6 


























                                       



























Figure 8.3:  Flow cytometric analysis of surface P6 in NTHi grown under anaerobic 
conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) and AlexaFluor® 
488 (FITC). Control #1 shows whole cells only. Control #2 shows whole cells with 
secondary antibody only (AlexaFluor® 488). Panel #3 shows whole cells labeled with 
anti-P6 and secondary antibody (Alexa Fluor® 488). The percentages of labeled 











































Figure 8.4: Flow cytometric analysis of surface P6 in NTHi grown under anaerobic 
conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) and AlexaFluor® 
488 (FITC). Control #1 shows whole cells only.  Control #2 shows whole cells with 
secondary antibody only (AlexaFluor® 488). Panel #3 shows whole cells labeled with 
anti-P6 and secondary antibody (Alexa Fluor® 488). The percentages of labeled 
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Figure 8.5: Flow cytometric analysis of surface P6 in NTHi grown under anaerobic 
conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) and AlexaFluor® 
488 (FITC). Control #1 shows whole cells only.  Control #2 shows whole cells with 
secondary antibody only (AlexaFluor® 488). Panels #3-6 show whole cells labeled with 
anti-P6 and increasing secondary antibody concentrations (0.25 µL, 0.75 µL, 1.25 µL, 
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Figure 8.6: Flow cytometric analysis of surface P6 in NTHi grown under anaerobic 
conditions. Cells were labeled with P6 antibodies (polyclonal anti-P6) and AlexaFluor 
647; BODIPY-Vancomycin labeled the peptidoglycan of compromised cells. Control #1 
shows whole cells only. Control #2 shows whole cells labeled with secondary antibody 
(Alexa Fluor® 647) only. Control #3 shows P6 labeling (y-axis) (no vancomycin). In the 
complete experiment, surface P6 is labeled (y-axis, Q1), peptidoglycan is labeled (x-axis, 
Q3), or both are labeled (Q2). The percentages of labeled populations are depicted in the 
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Anaerobic	  (%	  labeled	  cells)	  
Trial	  #	  
Without	  control	  for	  
dead/compromised	  cells	  	  
With	  control	  to	  exclude	  
dead/compromised	  cells	  
1	   3.4	   n/a	  
2	   3.6	   n/a	  
	  	  3*	   2.4	   n/a	  
4	   1.2	   1.9	  
Average	   2.6	   1.9	  
Standard	  Dev.	  	   1.0	   n/a	  	  
*Average of increasing secondary antibody trials, Figure 8.5. 
 
Table 7.0: Quantification of surface P6 in NTHi grown under anaerobic conditions using 
flow cytometry. Flow cytometric analysis allowed us to estimate the percentage of total 
NTHi cells with detectable surface P6. The left column shows the percentages of cells 
labeled with surface P6, but values may include labeling of dead/uncompromised cells; 
the right column shows the percentages of cells labeled with surface P6, and a 
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Comparison of Average P6 Populations, Nonbiotinylated: Biotinylated Ratios Between 





Figure 9.0: Graphical analysis of the average non-biotinylated and biotinylated P6 





Microaerophilic	   Anaerobic	  
Non-­‐Biotinylated	  %	   68	   60	  



















Microaerophilic	  Vs.	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Biotinylaiton	  Average	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Figure 9.1: Graphical analysis of the average flow cytometric results for surface P6 in 









(%)	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  Vancomycin	  (%)	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   9	   6	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Total P6 Expression Levels in NTHi Cultured in BHI Under Aerobic, Microaerophilic, 
and Anaerobic Conditions 
 
We determined the total P6 expression levels (inner and outer P6) in NTHi cultured under 
aerobic, microaerophilic, and anaerobic conditions. Results suggest that P6 expression 
levels vary when NTHi is grown under different oxygen levels; in particular, total P6 
expression levels are lowest when NTHi is grown under anaerobic conditions. We 






Figure 10.0: Detection of total P6 via polyclonal antibody in NTHi cultured under 
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Confocal Images of NTHi Cultured Under Different Oxygen Conditions 
 
Confocal microscopy was employed to determine the morphological changes in NTHi 
under varying oxygen conditions. Results from our confocal studies suggest that NTHi 
cells are under more environmental stress with decreasing levels of available oxygen. 
With lower levels of available oxygen, NTHi undergoes morphological changes from a 
rod-like cell structure (bacillus) to a spherical-shaped (coccus) cell structure. The 






Figure 11.0: Differential interference contrast image of NTHi grown under normal 
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Fluorescence-Activated Cell Sorting (FACS) of NTHi 
 
Original	  Growth	  	   Secondary	  Growth	  	  
Unlabeled	  %	   Labeled	  %	   Unlabeled	  %	   Labeled	  %	  
97	   3	   95	   5	  
Figure 12.0: FACS experiments allowed us to separate the labeled cells (those with 
surface P6) from the unlabeled cells (those without surface P6). The unlabeled cells were 
used to seed a secondary growth, which was re-labeled with anti-P6. Flow cytometry was 
employed to measure the percentages of labeled and unlabeled cells from the second 
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4. Discussions  
 
 
Surface P6 Labeling Experiments 
 NTHi is a facultative anaerobic organism; while it prefers the presence of oxygen, 
it is capable of surviving without it via fermentation [94]. In both the biotinylation 
experiments and flow cytometric analyses we observed small differences in the 
expression levels of surface exposed P6. However, we consistently detected higher levels 
of surface exposed P6 in the biotinylation experiments compared to the flow cytometry 
experiments. Here we discuss the differences between the two experiments and the 
corresponding analyses of our results. In the biotinylation experiment, we employed a 
biotin-labeling molecule (NHS-LC-LC-biotin), which covalently bound to lysine (and 
possible arginine) residues or free amine groups within the proteins. Therefore, multiple 
biotin molecules can conjugate to the same protein depending on how many lysine 
residues it contains. In the 134-residue protein sequence of NTHi P6 (PDB ID: 2AIZ) 
there are 7 lysine residues 
(CSSSNNDAAGNGAAQTFGGYSVADLQQRYNTVYFGFDKYDITGEYVQILDAHA
AYLNATPAAKVLVEGNTDERGTPEYNIALGQRRADAVKGYLAGKGVDAGKLG
TVSYGEEKPAVLGHDEAAYSKNRRAVLAY). Therefore, there are potentially 7 spots 
on P6 which could be used to “tag” to the protein as surface exposed. In the flow 
cytometry experiments, surface P6 is labeled via antibodies. Antibody promiscuity 
experiments were previous completed to determine if P6 specific antibodies were binding 
other surface proteins on NTHi. The results of these experiments verified that P6 
antibodies were not binding indiscriminately; anti-P6 monoclonal antibodies bound 
solely to P6 (data not shown). Monoclonal antibodies also bind to one specific epitope on 
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the protein. If access to that epitope is hindered by cell surface crowding, for example, 
then antibody binding would be limited. Therefore, we often observed much lower levels 
of binding to surface P6 via our flow cytometric analysis compared to what we observed 
in our biotinylation experiments. In addition, the biotinylation experiment yielded 
relatively variable results, compared to the flow experiments, perhaps due to the more 
complicated biotinylation labeling protocol. We, therefore, propose that the results from 
the flow cytometry experiments provided more reliable results than those from the 
biotinylation experiments.   
 
P6 Surface Expression in Multiple Strains of NTHi 
 By employing biotinylation experiments and flow cytometry, we found that the 
levels of surface expressed P6 are modest in multiple clinical strains of NTHi, with little 
variation among most strains. For the biotinylation experiments performed on 8 different 
NTHi strains the variation in the average amount of surface P6 ranged from 4-37%. 
However, excluding strain 13-02-538 V3 NWB (Manticore) the average surface P6 
expression for the remaining 7 strains is between 13-37%. 
 Only 6 strains were analyzed via flow cytometry. The average amount of 
extracellular P6 expression (with vancomycin control) ranged from 3-17%, with an 
average of ~10% extracellular P6 amongst 6 strains. In other words, out of 100 individual 
NTHi cells, between 3 and 17 of those cells displayed P6 on their surface. P6 is highly 
conserved among most of NTHi strains [57], suggesting that it serves an important 
function. Although the exact biological function is unknown, P6 is thought to play a role 
in maintaining cell membrane stability. Here, we show that P6 surface expression is also 
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conserved among strains (or at least among the clinical strains that we tested). This 
evidence supports P6’s vaccine candidacy, although it is unclear how/why only a small 
fraction of total NTHi cells (in any given population) express P6 on their cell surface.  
 
P6 Surface Expression in NTHi Cultured at Different pH’s 
 The results of our biotinylation experiments on NTHi grown in BHI at various pH 
values suggest that NTHi grown at pH 7.5 yields the greatest levels of surface P6. 
However, there is a rather large standard deviation for each value found for all four 
biologically relevant pH values (pH 7, 7.5, 8, and 8.5). The surface P6 levels for each pH 
value are all within one standard deviation of each other, suggestion that pH does not 
affect the surface expression levels of P6. Importantly, though, we have shown here that 
P6 is surface exposed in NTHi expressed at all of the biologically relevant pH values.  
The flow cytometry experiments, though, provided more insight into the effect of 
pH on P6 surface exposure. Our results show a positive correlation between P6 surface 
exposure and increased pH. The average percentages of labeled cells (i.e., the average 
percentage of cells exhibiting surface P6) were as followed: 2% (pH 7), 2% (pH 7.5), 4% 
(pH 8), and 5% (pH 8.5).   
Unlike purulent material that has an acidic pH, middle ear fluid (MEF) has a 
slightly alkaline pH of approximately 8 [94, 95]. The alkalinity of the MEF is beneficial 
to NTHi because it stimulates the solubility of hemin, making uptake for metabolic use 
easier for NTHi [94, 96]. NTHi captures heme through the ferric uptake regulator (Fur). 
The uptake of heme from the environment is critical due to NTHi not having the ability to 
synthesize heme itself [97, 98]. Fur can also influence the transcription of genes for 
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proteins involved in pH homeostasis, oxidative stress, quorum sensing, among other 
cellular functions [99-101]. Microenvironments have been known to impact gene 
expression. The results of our work suggest that the alkaline microenvironment of the 
MEF in the inner ear leads to greater surface P6 expression [97]. This alkaline 
environment also makes it easier for hemin to be acquired by NTHi via Fur; we 
hypothesize that Fur (or another pH dependent protein) may play an important role in 
modulating P6 surface expression.  
 
P6 surface expression in NTHi grown under microaerophilic and anaerobic conditions 
We did observe changes in P6 surface expression in NTHi strain 86-028 (WT) 
when expressed under variable oxygen conditions, although the changes were relatively 
modest. Flow cytometry experiments showed low levels of P6 surface expression in 
NTHi grown under anaerobic conditions (~2%), and a slightly higher levels of surface 
exposed P6 in NTHi grown under microaerophilic conditions (~6%). On average, we 
observed ~2-3%5 cells with surface exposed P6 in NTHi grown under aerobic conditions. 
 We are unclear why surface P6 levels would increase under microaerophilic 
conditions, but we conclude that under any physiologically relevant level of oxygen 
availability, at least some NTHi cells will exhibit P6 on their cell surface.  
 
NTHi Morphology 
 NTHi is a small Gram-negative coccobacilli bacterium. It has an oval phenotype 
between the coccus and bacillus typing [102]. Some differences in phenotypic diversity 
has been noted when NTHi is compared in individuals that are infected with NTHi and 
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those that have NTHi within their normal flora (as a commensal organism) [102, 103]. 
Microbiologists have noticed morphological changes in bacteria with changes in growth 
rate and nutritional conditions. They have shown that it is common for bacteria to alter 
their morphology in response to external molecules or compounds [104]. This 
phenomenon was also seen in the oxygen manipulation experiments, where NTHi was 
cultured under microaerophilic and anaerobic conditions. The confocal microscopy 
images revealed an increased trend toward the coccus shape over the natural rod-like 
appearance. We explain this trend with the hypothesis that bacteria under stress have the 
ability to accelerate or delay cellular division; as such, the bacteria exhibit changes to 
their cell size and shape, becoming longer or shorter then normally observed. Typically, 
when bacteria are nutrient-deprived or cultured under an environmental stressor (such as 
lack of oxygen), the cells elongate in order to increase their surface area and allow for 
greater uptake of nutrients/oxygen [104]. Therefore, we propose that the uniform circular 
morphology of the NTHi that we observed is the result of the bacteria preparing for the 
partitioning of its cytoplasmic contents during division. Asymmetric cellular 
morphologies can lead to uneven sharing of material, and therefore result in nonviable 
daughter cells [104]. Additionally, uniform cell shape may aid in interaction with other 
cells within the same bacterial species or those of the host species [104]. 
Other possible explanations for the morphological switch may be that for bacteria 
in an aqueous environment, where movement is solely dictated by diffusion (bacteria not 
in an ocean, lake, stream, etc., that is largely impacted by currents), sphere-shaped 
bacteria move the most rapidly via Brownian motion. The rate of diffusion decreases in 
disk-shaped bacteria and decreases even further for rod or bacillus-shaped bacteria [104, 
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105].  Therefore, if the bacterial species has no propulsion source, like a flagellum, 
coccus is the best shape to take on for non-motile bacteria such as NTHi. The coccus-
shaped bacteria also exhibit the fastest rate of sedimentation (followed by disk-shaped 
then bacillus) [104, 106]. We therefore propose that under oxygen-deprived conditions, 
the NTHi may alter their morphology to aggregate and sediment quickly, thus allowing 
them to form a protective biofilm which will allow them to withstand the harsh 
environmental conditions.  
Low-nutrient environments and bacteriophage pressure are comparable; in that 
both factors regularly push bacteria into generating a smaller cellular morphology. If 
bacteria cells are smaller in size, then subsequent phage infection and lysis will lead to a 
smaller loss in biomass. Phages are also able to bind and infect larger cells with higher 
frequency compared to smaller bacteria cells [104, 107]. 
Lastly, environmental factors (chemical or physical) will be spread over more 
individual bacteria if the cell size is smaller. In this case, bacteria act for the “greater 
good,” allowing more of the bacteria to survive [104, 108]. Taken together, there are 
many scientifically reasonable explanations to why restricting oxygen results in coccus-
shaped NTHi; however, we propose the change in morphology allows the bacteria to 
more easily form a biofilm.  
 
Fluorescence-Activated Cell Sorting (FACS) 
 We also performed an additional flow cytometry cell sorting experiment. In the 
fluorescence-activated cell sorting (FACS) experiment, the surface P6 (in NTHi strain 
86-028) were labeled with fluorescent antibodies and passed through a flow cytometer (as 
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with the above experiments). In FACS, though, we were able to sort the two populations 
of NTHi: 1) NTHi containing labeled surface P6 (“labeled” population) and 2) 
“unlabeled” NTHi (no surface P6). We performed these FACS experiments at the Flow 
Core at the University of Rochester Medical Center. We observed typical surface P6 
labeling (~3% of the NTHi cells were labeled with P6 antibodies on their cell surface). 
Due to the small size of NTHi, we encountered challenges in sorting, and were unable to 
reliably collect the 100% “labeled” population. We were able to collect the 100% 
“unlabeled” population, though, which we used to seed a new NTHi growth. That seed 
culture was allowed to grow to an OD of ~0.8, at which point we repeated the normal 
anti-P6 labeling process. Flow cytometric analysis of this new growth showed labeling 
similar to the original NTHi growth (with ~3% surface labeling), suggesting that cells 
which do not display surface P6 during any given experiment have the potential to A) 














 For the last three decades, the lipoprotein P6 has been a leading vaccine candidate 
for the protection against pathogenic bacteria Nontypeable Haemophilus influenzae. Two 
years ago, we discovered that P6 exhibited a unique dual orientation for which we 
described two populations of P6: one population which was surface exposed and one 
population which was internally localized.  
Here, we described our efforts to further elucidate the two orientations of P6 in 
multiple clinical strains of NTHi cultured under various environmental conditions. Our 
results suggest that surface P6 expression is only slightly variable between the multiple 
clinical strains that we tested (~4-37% cells exhibit surface exposed P6, from 
biotinylation labeling and ~3-17% cells exhibit surface exposed P6, from flow analysis). 
We conclude that expression of P6 and its dual orientation is highly conserved among 
the strains of NTHi. We have yet to understand the biological role of P6 dual orientation 
or its mechanism. Another long term goal for our group will be to assess the effect of 
limited P6 surface exposure on its role as a vaccine candidate.  
 We also showed that surface P6 levels are relatively consistent among NTHi 
grown at different, biologically relevant pH values. We did see, however, a slight trend of 
increased P6 surface exposure for NTHi cultured at higher pH values (flow cytometric 
analysis). We conclude that within the physiological pH range of the inner ear and 
nasal cavity, surface P6 exposure is relatively consistent in NTHi, with a slight 
increase of surface exposure at elevated pH values.  
 Finally, we assessed changes to P6 surface exposure in NTHi cultured with 
limited oxygen availability. During OM, the microenvironment within the ear changes, 
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and exposure to oxygen can become limited. We found that surface P6 levels varied 
between oxygen conditions, with ~3% cells with surface P6 under aerobic conditions, 
~2% cells with surface P6 under anaerobic conditions, and 6.7% cells with surface P6 
under microaerophilic conditions (NTHi strain 86-028 (WT)). We conclude that P6 
surface exposure is optimal under microaerophilic conditions, which we predict to be 
the most common condition in the inner during OM/OME; however, P6 surface 
exposure can be found in NTHi cultured under any level of oxygen availability.  We 
also noted that different levels of oxygen availability alter NTHi cell morphology, as well 
as total P6 expression levels (which are most limited under anaerobic conditions).  
 Finally, we conclude from our studies that P6 remains a leading vaccine candidate 
for the protection against infection by NTHi. We were able to demonstrate, for the first 
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